Market Currents
Flamel Technologies (FLML) -19% premarket after agreeing to acquire specialty drug maker Eclat...
-
Thursday, March 15, 2012, 9:29 AM ETFlamel Technologies (FLML) -19% premarket after agreeing to acquire specialty drug maker Eclat Pharmaceuticals in a debt-and-warrant deal and named Eclat's chief executive to replace its own CEO.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
